CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.
A single dose of the chimeric antigen receptor T-cell therapy reduced the risk for disease progression or death by 74% compared with either of two standard-of-care regimens, according to data presented at ASCO Annual Meeting and published in The New England Journal of Medicine.
“Median overall survival in this patient population is poor, at approximately 9 months,”
